TOP NEWS: AstraZeneca sells Ohio manufacturing site

(Alliance News) - AstraZeneca PLC on Wednesday announced the sale of its West Chester ...

Alliance News 30 November, 2022 | 9:19AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Wednesday announced the sale of its West Chester manufacturing site in the US state of Ohio to National Resilience Inc.

The Cambridge-based pharmaceutical company gave no financial details of the sale.

National Resilience is a technology-focused manufacturing firm.

AstraZeneca said it expects to complete the sale in the first quarter of 2023, with a phased transition of services.

Andrew Wirths, senior vice president of the Americas Supply Region at AstraZeneca, said the sale is part of the company's "long-term strategy to ensure our global supply network remains fit for the future."

Resilience Chief Executive Officer Rahul Singhvi said: "The West Chester site will play an important role in the delivery of our mission to broaden access to complex medicines, protect biopharmaceutical supply chains, and strengthen domestic preparedness."

The West Chester site is a 580,000 square-foot facility, equipped with end-to-end drug product manufacturing capabilities such as aseptic filling, inspection, packaging, labeling, and cold-chain operations for vials, cartridges, and so on.

Yesterday, AstraZeneca said it agreed to buy Neogene Therapeutics Inc, a clinical stage biotechnology company focused on the discovery, development and manufacturing of T-cell receptor therapies, for up to USD320 million for the treatment of cancer.

Shares were up 0.5% at 11,116.00 pence each on Wednesday morning in London.

By Xindi Wei; xindiwei@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 11,988.00 GBX -0.32

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures